<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501811</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-SPH-15-0413</org_study_id>
    <secondary_id>5UM1HL087318</secondary_id>
    <nct_id>NCT02501811</nct_id>
  </id_info>
  <brief_title>Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure</brief_title>
  <acronym>CONCERT-HF</acronym>
  <official_title>A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, &amp; Efficacy of Autologous Mesenchymal Stem Cells &amp; C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, randomized, placebo-controlled clinical trial designed to assess&#xD;
      feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells&#xD;
      (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free&#xD;
      Plasmalyte-A medium) as well as each other, administered by transendocardial injection in&#xD;
      subjects with ischemic cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled clinical trial designed to evaluate the feasibility,&#xD;
      safety, and effect of Combo, MSCs alone, and c-kit+ cells alone compared with placebo as well&#xD;
      as each other in subjects with heart failure of ischemic etiology. Following a successful&#xD;
      lead-in phase, a total of one hundred forty-four (144) subjects will be randomized (1:1:1:1)&#xD;
      to receive Combo, MSCs, c-kit+ cells, or placebo. After randomization, baseline imaging,&#xD;
      relevant harvest procedures, and study product injection, subjects will be followed up at 1&#xD;
      day, 1 week, 1 month, 3 months, 6 months and 12 months post study product injection. All&#xD;
      subjects will receive study product injection (cells or placebo) using the NOGA® XP Mapping&#xD;
      and Navigation System. Subjects will have delayed-enhanced magnetic resonance imaging (DEMRI)&#xD;
      scans to assess scar size and LV function and structure at baseline and at 6 and 12 months&#xD;
      post study product administration. All endpoints will be assessed at the 6 and 12 month&#xD;
      visits which will occur 180 ±30 days and 365 ±30 days respectively from the day of study&#xD;
      product injection (Day 0). For the purpose of the endpoint analysis and safety evaluations,&#xD;
      the Investigators will utilize an &quot;intention-to-treat&quot; study population, however an as&#xD;
      treated analysis will also be conducted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 22, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in left ventricular ejection fraction as assessed via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Global Strain (HARP MRI)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in global circumferential strain as assessed via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Regional Strain (HARP MRI)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in regional longitudinal strain as assessed via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in left ventricular end diastolic volume index as measured via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in left ventricular end systolic volume index as assessed via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular Sphericity Index</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in left ventricular sphericity as assessed via cardiac MRI. Sphericity index is the ratio of the long and short axis measurements of the left ventricle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Scar Size Percent (DEMRI)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in scar size percent as assessed via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Scar Tissue Mass (DEMRI)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in scar tissue mass as assessed via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Maximal Oxygen Consumption (Peak VO2)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in maximal oxygen consumption (peak V02) as assessed via treadmill</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Exercise Tolerance (Six Minute Walk Test)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in distance walked (in meters) as measured by the 6 minute walk test. Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in the quality of life summary score as measured by the Minnesota Living with Heart Failure Questionnaire. Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via laboratory blood draw</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Global Strain (HARP MRI)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Regional Strain (HARP MRI)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular Sphericity Index-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>Sphericity index is the ratio of the long and short axis measurements of the left ventricle. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Scar Size Percent (DEMRI)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The 2nd and 3rd set of results represent differences for varying slopes from the interaction model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory</measure>
    <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
    <description>Log transformation used. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection</time_frame>
    <description>Number of participants with adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants Experiencing Other Significant Clinical Events</measure>
    <time_frame>Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection</time_frame>
    <description>Number of participants experiencing other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Days Alive and Out of Hospital for Heart Failure</measure>
    <time_frame>Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection</time_frame>
    <description>Days alive and out of hospital during the study evaluation period. Subjects were allotted a visit window extending 30 days past their anticipated 12-month visit. Some participants had extended 12-month visit windows due to the COVID-19 pandemic.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Subjects With Events Between Randomization and Study Product Injection (SPI) That Preclude the Receipt of Product</measure>
    <time_frame>Randomization to SPI, an average of 14 weeks</time_frame>
    <description>Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product. Reasons include those who did not undergo harvest (n=6; death, subject withdraw, subject changed mind) and those who did not undergo SPI (n=9; death, LVAD placement, episodes of ventricular tachycardia, and cancelled procedures)</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects Who Have a Failed Bone Marrow Aspiration Procedure</measure>
    <time_frame>During bone marrow aspiration procedure</time_frame>
    <description>Number and percent of subjects who do not successfully undergo bone marrow aspiration</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects Who Have a Failed Endomyocardial Biopsy Procedure</measure>
    <time_frame>During endomyocardial biopsy procedure</time_frame>
    <description>Number and percent of subjects who do not successfully undergo endomyocardial biopsy procedure. Note only participants who were assigned to MSC+CPC or to CPC groups had endomyocardial biopsy procedures attempted.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject MSC Products Which Failed Release Criteria</measure>
    <time_frame>Harvest to Study Product Injection Procedure</time_frame>
    <description>Number and percent of subjects who have MSC products which failed release criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject CPC Products Which Failed Release Criteria</measure>
    <time_frame>Harvest to Study Project Injection procedure</time_frame>
    <description>Number and percent of subjects who have CPC products which failed release criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects Who Receive Less Than 15 Injections During SPI</measure>
    <time_frame>During SPI procedure</time_frame>
    <description>Number and percent of subjects who received less than 15 injections during SPI</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cells (MSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target dose of 150 million MSCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>c-kit+ cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target dose of 5 million c-kit+ cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cells (MSC and c-kit+ cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target dose of 150 million MSCs and 5 million c-kit+ cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Plasmalyte A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Plasmalyte A</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cells (MSC)</intervention_name>
    <description>15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)</description>
    <arm_group_label>Combination Cells (MSC and c-kit+ cells)</arm_group_label>
    <arm_group_label>Mesenchymal Stem Cells (MSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>c-kit+ cells</intervention_name>
    <description>15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)</description>
    <arm_group_label>Combination Cells (MSC and c-kit+ cells)</arm_group_label>
    <arm_group_label>c-kit+ cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (Plasmalyte A)</intervention_name>
    <description>15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)</description>
    <arm_group_label>Placebo (Plasmalyte A)</arm_group_label>
    <other_name>Plasmalyte A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be ≥ 21 and &lt;80 years of age&#xD;
&#xD;
          2. Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV&#xD;
             dysfunction, and clinical evidence of HF&#xD;
&#xD;
          3. Have a &quot;detectable&quot; area of myocardial injury defined as ≥ 5% LV involvement (infarct&#xD;
             volume) and any subendocardial involvement by cMRI&#xD;
&#xD;
          4. Have an EF ≤ 40% by cMRI&#xD;
&#xD;
          5. Be receiving guideline-driven medical therapy for heart failure at stable and&#xD;
             tolerated doses for ≥ 1 month prior to consent. For beta-blockade &quot;stable&quot; is defined&#xD;
             as no greater than a 50% reduction in dose or no more than a 100% increase in dose.&#xD;
&#xD;
          6. Be a candidate for cardiac catheterization&#xD;
&#xD;
          7. Have NYHA class I, II, or III heart failure symptoms&#xD;
&#xD;
          8. If a female of childbearing potential, be willing to use one form of birth control for&#xD;
             the duration of the study, and undergo a pregnancy test at baseline and within 36&#xD;
             hours prior to injection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Indication for standard-of-care surgery (including valve surgery, placement of&#xD;
             left-ventricular assist device, or imminent heart transplantation), coronary artery&#xD;
             bypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI) for&#xD;
             the treatment of ischemic and/or valvular heart disease. Subjects who require or&#xD;
             undergo PCI should undergo these procedures a minimum of 3 months in advance of&#xD;
             randomization. Subjects who require or undergo CABG should undergo these procedures a&#xD;
             minimum of 4 months in advance of randomization. In addition, subjects who develop a&#xD;
             need for revascularization following enrollment should undergo revascularization&#xD;
             without delay. Indication for imminent heart transplantation is defined as a high&#xD;
             likelihood of transplant prior to collection of the 12 month study endpoint.&#xD;
             Candidates cannot be UNOS status 1A or 1B, and they must have documented low&#xD;
             probability of being transplanted&#xD;
&#xD;
          2. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2)&#xD;
             severe (any valve) insufficiency/regurgitation within 12 months of consent&#xD;
&#xD;
          3. Aortic stenosis with valve area ≤ 1.5 cm2&#xD;
&#xD;
          4. History of ischemic or hemorrhagic stroke within 90 days of consent&#xD;
&#xD;
          5. History of a left ventricular remodeling surgical procedure utilizing prosthetic&#xD;
             material&#xD;
&#xD;
          6. Presence of a pacemaker and/or implantable cardioverter-defibrillator (ICD) generator&#xD;
             with any of the following limitations/conditions:&#xD;
&#xD;
               -  manufactured before the year 2000&#xD;
&#xD;
               -  leads implanted &lt; 6 weeks prior to consent&#xD;
&#xD;
               -  non-transvenous epicardial, or abandoned leads&#xD;
&#xD;
               -  subcutaneous ICDs&#xD;
&#xD;
               -  leadless pacemakers&#xD;
&#xD;
               -  any other condition that, in the judgment of device-trained staff, would deem an&#xD;
                  MRI contraindicated&#xD;
&#xD;
          7. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD&#xD;
             are not excluded)&#xD;
&#xD;
          8. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to&#xD;
             consent&#xD;
&#xD;
          9. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)&#xD;
&#xD;
         10. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular&#xD;
             fibrillation or ventricular tachycardia within 30 days of consent&#xD;
&#xD;
         11. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of&#xD;
             consent, or symptomatic Mobitz II or higher degree atrioventricular block without a&#xD;
             functioning pacemaker within 3 months of consent&#xD;
&#xD;
         12. Presence of LV thrombus&#xD;
&#xD;
         13. Evidence of active myocarditis&#xD;
&#xD;
         14. Baseline maximal oxygen consumption (VO2 max) greater than 75% of age and gender based&#xD;
             predictive values&#xD;
&#xD;
         15. Baseline eGFR &lt;35 ml/min/1.73m2&#xD;
&#xD;
         16. Blood glucose levels (HbA1c) &gt;10%&#xD;
&#xD;
         17. Hematologic abnormality evidenced by hematocrit &lt; 25%, white blood cell &lt; 2,500/ul or&#xD;
             platelet count &lt; 100,000/ul&#xD;
&#xD;
         18. Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
         19. Coagulopathy (INR ≥ 1.3) not due to a reversible cause (e.g., warfarin and/or Factor&#xD;
             Xa inhibitors). Subjects who cannot be withdrawn from anticoagulation will be&#xD;
             excluded.&#xD;
&#xD;
         20. HIV and/or active hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
         21. Allergy to radiographic contrast material that cannot adequately be managed by&#xD;
             premedication&#xD;
&#xD;
         22. Known history of anaphylactic reaction to penicillin or streptomycin&#xD;
&#xD;
         23. Received gene or cell-based therapy from any source within the previous 12 months&#xD;
&#xD;
         24. History of malignancy within 5 years (i.e., subjects with prior malignancy must be&#xD;
             disease free for 5 years), excluding basal cell carcinoma and cervical carcinoma in&#xD;
             situ which have been definitively treated&#xD;
&#xD;
         25. Condition that limits lifespan to &lt; 1 year&#xD;
&#xD;
         26. History of drug abuse (illegal &quot;street&quot; drugs except marijuana, or prescription&#xD;
             medications not being used appropriately for a pre-existing medical condition) or&#xD;
             alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or&#xD;
             legal problems arising from the use of alcohol or drugs within the past 24 months&#xD;
&#xD;
         27. Participation in an investigational therapeutic or device trial within 30 days of&#xD;
             consent&#xD;
&#xD;
         28. Cognitive or language barriers that prohibit obtaining informed consent or any study&#xD;
             elements&#xD;
&#xD;
         29. Pregnancy or lactation or plans to become pregnant in the next 12 months&#xD;
&#xD;
         30. Any other condition that, in the judgment of the Investigator or Sponsor, would impair&#xD;
             enrollment, study product administration, or follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Simari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CCTRN Steering Committee Chair</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine (Falk Cardiovascular Research Center)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida-Department of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami-Interdisciplinary Stem Cell Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Center for Vascular Biology and Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cctrn.org</url>
    <description>Cardiovascular Cell Therapy Research Network</description>
  </link>
  <link>
    <url>http://www.nhlbi.nih.gov</url>
    <description>National Heart, Lung, and Blood Institute</description>
  </link>
  <link>
    <url>https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/stem-cells</url>
    <description>Information on stem cells from the National Institutes of Health</description>
  </link>
  <reference>
    <citation>Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moyé LA; Cardiovascular Cell Therapy Research Network. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation. 2013 Apr 16;127(15):1630-5. doi: 10.1161/CIRCULATIONAHA.112.000779.</citation>
    <PMID>23588961</PMID>
  </reference>
  <reference>
    <citation>Nazarian S, Halperin HR. How to perform magnetic resonance imaging on patients with implantable cardiac arrhythmia devices. Heart Rhythm. 2009 Jan;6(1):138-43. doi: 10.1016/j.hrthm.2008.10.021. Epub 2008 Oct 22. Review.</citation>
    <PMID>19121814</PMID>
  </reference>
  <reference>
    <citation>Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit(+) Cardiac Stem Cells As Regenerative Therapy for Heart Failure). Circ Res. 2018 Jun 8;122(12):1703-1715. doi: 10.1161/CIRCRESAHA.118.312978. Epub 2018 Apr 27.</citation>
    <PMID>29703749</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <results_first_submitted>February 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2021</results_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Barry R Davis</investigator_full_name>
    <investigator_title>Professor of Biostatistics</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Autologous Stem Cells</keyword>
  <keyword>LV dysfunction</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>c-kit+ Cells</keyword>
  <keyword>Combination Cell Therapy</keyword>
  <keyword>LV function</keyword>
  <keyword>Functional status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment took place at seven CCTRN centers between November 2016 and November 2018. The main centers are located in Texas, Florida (2 locations), Minnesota, Kentucky, Indiana, and California. Recruitment methods included www.clinicaltrials.gov, local heart failure clinics, and outreach to physician cardiologists. Original sample size of 144 was capped at 125 by NHLBI following review by DSMB of cell production, interim analysis, and power calculations. Power deemed adequate at 125 subjects.</recruitment_details>
      <pre_assignment_details>125 individuals consented, completed baseline testing, met eligibility criteria, and were randomized to study group. Reasons for failed eligibility (n=68) included investigator discretion, elevated LVEF, MRI contraindications, LV thrombus requiring anticoagulation therapy, elevated peak VO2, and other.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MSCs + CPCs</title>
          <description>Target dose of 150 million MSCs and 5 million CPCs</description>
        </group>
        <group group_id="P2">
          <title>MSCs</title>
          <description>Target dose of 150 million MSCs</description>
        </group>
        <group group_id="P3">
          <title>CPCs</title>
          <description>Target dose of 5 million CPCs</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Plasmalyte A</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29">includes 1 participant who completed final study visit but died within 30 days after final visit.</participants>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25">includes 1 participant who completed final study visit but died within 30 days after final visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Denominators are of those reporting</population>
      <group_list>
        <group group_id="B1">
          <title>MSCs + CPCs</title>
          <description>Target dose of 150 million MSCs and 5 million CPCs</description>
        </group>
        <group group_id="B2">
          <title>MSCs</title>
          <description>Target dose of 150 million MSCs</description>
        </group>
        <group group_id="B3">
          <title>CPCs</title>
          <description>Target dose of 5 million CPCs</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Plasmalyte A</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="11.1"/>
                    <measurement group_id="B2" value="61.7" spread="6.7"/>
                    <measurement group_id="B3" value="64.2" spread="8.1"/>
                    <measurement group_id="B4" value="63.1" spread="8.0"/>
                    <measurement group_id="B5" value="62.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="3.5"/>
                    <measurement group_id="B2" value="30.4" spread="5.4"/>
                    <measurement group_id="B3" value="29.4" spread="5.0"/>
                    <measurement group_id="B4" value="30.0" spread="4.4"/>
                    <measurement group_id="B5" value="30.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118.4" spread="18.2"/>
                    <measurement group_id="B2" value="114.0" spread="11.3"/>
                    <measurement group_id="B3" value="117.3" spread="17.9"/>
                    <measurement group_id="B4" value="117.2" spread="17.6"/>
                    <measurement group_id="B5" value="116.8" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="9.3"/>
                    <measurement group_id="B2" value="70.1" spread="9.0"/>
                    <measurement group_id="B3" value="68.3" spread="10.8"/>
                    <measurement group_id="B4" value="67.7" spread="11.2"/>
                    <measurement group_id="B5" value="69.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <population>One participant missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <population>One participant missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking (Lifetime)</title>
          <description>Smoking (Lifetime) includes previous and current smokers</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Hospitalization for Heart Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Emergency Department Visit for Heart Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ongoing Ischemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association Class 1</title>
          <description>Physician's use the NYHA classification system to place patients into one of four categories based on how much they are limited during physical activity. Class 1 is characterized by no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association Class 2</title>
          <description>Physician's use the NYHA classification system to place patients into one of four categories based on how much they are limited during physical activity. Class 2 is characterized by slight limitation of physical activity. The patient is comfortable at rest, however ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association Class 3</title>
          <description>Physician's use the NYHA classification system to place patients into one of four categories based on how much they are limited during physical activity. Class 3 is characterized by marked limitation of physical activity. The patient is comfortable at rest, however less than ordinary activity causes fatigue, palpitation, or dyspnea.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of a Cardiac Device</title>
          <description>Presence of an internal cardiac defibrillator (ICD) or biventricular pacing and ICD.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Myocardial Infarctions</title>
          <description>Number of Myocardial Infarctions (lifetime)</description>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="1.0"/>
                    <measurement group_id="B2" value="1.9" spread="1.7"/>
                    <measurement group_id="B3" value="1.9" spread="1.2"/>
                    <measurement group_id="B4" value="1.7" spread="1.0"/>
                    <measurement group_id="B5" value="1.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percutaneous Coronary Intervention (PCI)</title>
          <description>Variable represents number of patients having undergone PCI procedures (lifetime).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Bypass Grafting (CABG)</title>
          <description>Variable represents the number of patients having undergone a CABG procedure (lifetime).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multi-Vessel Disease</title>
          <description>Multiple vessels supplying blood flow to the left ventricle are affected</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial Fibrillation</title>
          <description>Variable represents number of patients experiencing atrial fibrillation (lifetime)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sustained Ventricular Arrhythmia</title>
          <description>Variable represents the number of patients experiencing sustained ventricular arrhythmia (lifetime)</description>
          <population>One participant missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Valvular Heart Disease</title>
          <description>Variable represents the number of patients diagnosed with valvular heart disease (lifetime)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta Blockers</title>
          <description>Baseline medications include the use of beta blockers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ACE Inhibitors</title>
          <description>Baseline medications include the use of angiotensin converting enzyme inhibitors (ACE inhibitors)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin II Blockers</title>
          <description>Baseline medications included the use of angiotensin II blockers</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Entresto</title>
          <description>Baseline medications included the use of Entresto</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aldosterone Antagonists</title>
          <description>Baseline medications included the use of aldosterone antagonists</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular Ejection Fraction (LVEF)</title>
        <description>Change in left ventricular ejection fraction as assessed via cardiac MRI</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable LVEF at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular Ejection Fraction (LVEF)</title>
          <description>Change in left ventricular ejection fraction as assessed via cardiac MRI</description>
          <population>Participants with available analyzable LVEF at baseline and 6 months</population>
          <units>percentage of end diastolic volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="3.90"/>
                    <measurement group_id="O2" value="0.37" spread="2.95"/>
                    <measurement group_id="O3" value="1.05" spread="3.68"/>
                    <measurement group_id="O4" value="-0.33" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.993</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEF was compared using ANCOVA analyses adjusting for baseline values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.190</ci_lower_limit>
            <ci_upper_limit>2.023</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.499</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEF was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.229</ci_lower_limit>
            <ci_upper_limit>2.635</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.578</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEF was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.729</ci_lower_limit>
            <ci_upper_limit>3.485</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.523</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEF was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.552</ci_lower_limit>
            <ci_upper_limit>0.629</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.471</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEF was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>1.127</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.485</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEF was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.240</ci_lower_limit>
            <ci_upper_limit>2.590</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Global Strain (HARP MRI)</title>
        <description>Change in global circumferential strain as assessed via cardiac MRI</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable global circumferential strain at baseline and 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Strain (HARP MRI)</title>
          <description>Change in global circumferential strain as assessed via cardiac MRI</description>
          <population>Participants with available analyzable global circumferential strain at baseline and 6 months.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="3.20"/>
                    <measurement group_id="O2" value="0.48" spread="3.36"/>
                    <measurement group_id="O3" value="0.56" spread="2.08"/>
                    <measurement group_id="O4" value="-0.10" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.942</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in global circumferential strain was compared using ANCOVA analyses adjusting for baseline values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.406</ci_lower_limit>
            <ci_upper_limit>1.887</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in global circumferential strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.815</ci_lower_limit>
            <ci_upper_limit>2.975</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in global circumferential strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.310</ci_lower_limit>
            <ci_upper_limit>2.635</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in global circumferential strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.471</ci_lower_limit>
            <ci_upper_limit>0.628</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.329</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in global circumferential strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.932</ci_lower_limit>
            <ci_upper_limit>1.254</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.752</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in global circumferential strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.829</ci_lower_limit>
            <ci_upper_limit>1.994</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Regional Strain (HARP MRI)</title>
        <description>Change in regional longitudinal strain as assessed via cardiac MRI</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable regional longitudinal strain at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Regional Strain (HARP MRI)</title>
          <description>Change in regional longitudinal strain as assessed via cardiac MRI</description>
          <population>Participants with available analyzable regional longitudinal strain at baseline and 6 months</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="2.33"/>
                    <measurement group_id="O2" value="-0.51" spread="2.33"/>
                    <measurement group_id="O3" value="-0.76" spread="2.49"/>
                    <measurement group_id="O4" value="-0.91" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in regional longitudinal strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.118</ci_lower_limit>
            <ci_upper_limit>1.927</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.735</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in regional longitudinal strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.248</ci_lower_limit>
            <ci_upper_limit>2.041</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.794</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in regional longitudinal strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.464</ci_lower_limit>
            <ci_upper_limit>1.767</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.951</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in regional longitudinal strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.161</ci_lower_limit>
            <ci_upper_limit>1.666</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.962</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in regional longitudinal strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.441</ci_lower_limit>
            <ci_upper_limit>1.457</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in regional longitudinal strain was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.793</ci_lower_limit>
            <ci_upper_limit>1.303</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)</title>
        <description>Change in left ventricular end diastolic volume index as measured via cardiac MRI</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable LVEDVI at baseline and six months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)</title>
          <description>Change in left ventricular end diastolic volume index as measured via cardiac MRI</description>
          <population>Participants with available analyzable LVEDVI at baseline and six months</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="16.06"/>
                    <measurement group_id="O2" value="0.21" spread="11.91"/>
                    <measurement group_id="O3" value="-1.13" spread="12.37"/>
                    <measurement group_id="O4" value="2.99" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEDVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.754</ci_lower_limit>
            <ci_upper_limit>5.711</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.443</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEDVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.609</ci_lower_limit>
            <ci_upper_limit>4.044</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEDVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.011</ci_lower_limit>
            <ci_upper_limit>2.760</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.812</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEDVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.760</ci_lower_limit>
            <ci_upper_limit>9.968</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.900</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEDVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.052</ci_lower_limit>
            <ci_upper_limit>8.574</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.848</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVEDVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.321</ci_lower_limit>
            <ci_upper_limit>5.635</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)</title>
        <description>Change in left ventricular end systolic volume index as assessed via cardiac MRI</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable LVESVI at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)</title>
          <description>Change in left ventricular end systolic volume index as assessed via cardiac MRI</description>
          <population>Participants with available analyzable LVESVI at baseline and 6 months</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="11.17"/>
                    <measurement group_id="O2" value="-0.22" spread="10.75"/>
                    <measurement group_id="O3" value="-2.37" spread="11.09"/>
                    <measurement group_id="O4" value="2.23" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.659</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVESVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.281</ci_lower_limit>
            <ci_upper_limit>4.789</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.466</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVESVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.621</ci_lower_limit>
            <ci_upper_limit>3.710</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.293</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVESVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.799</ci_lower_limit>
            <ci_upper_limit>1.594</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVESVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.795</ci_lower_limit>
            <ci_upper_limit>9.508</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.761</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVESVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.910</ci_lower_limit>
            <ci_upper_limit>7.330</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.669</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in LVESVI was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.426</ci_lower_limit>
            <ci_upper_limit>4.132</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular Sphericity Index</title>
        <description>Change in left ventricular sphericity as assessed via cardiac MRI. Sphericity index is the ratio of the long and short axis measurements of the left ventricle.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable LV sphericity index at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular Sphericity Index</title>
          <description>Change in left ventricular sphericity as assessed via cardiac MRI. Sphericity index is the ratio of the long and short axis measurements of the left ventricle.</description>
          <population>Participants with available analyzable LV sphericity index at baseline and 6 months</population>
          <units>ratio-unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.07"/>
                    <measurement group_id="O2" value="-0.00" spread="0.07"/>
                    <measurement group_id="O3" value="0.00" spread="0.08"/>
                    <measurement group_id="O4" value="0.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.989</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in left ventricular sphericity index was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.048</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.493</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in left ventricular sphericity index was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.056</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.926</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in left ventricular sphericity index was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.904</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in left ventricular sphericity index was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.476</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in left ventricular sphericity index was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.515</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in left ventricular sphericity index was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Scar Size Percent (DEMRI)</title>
        <description>Change in scar size percent as assessed via cardiac MRI</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available and analyzable scar size data at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scar Size Percent (DEMRI)</title>
          <description>Change in scar size percent as assessed via cardiac MRI</description>
          <population>Participants with available and analyzable scar size data at baseline and 6 months</population>
          <units>percentage of mass</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="3.25"/>
                    <measurement group_id="O2" value="-0.70" spread="2.80"/>
                    <measurement group_id="O3" value="-1.06" spread="2.40"/>
                    <measurement group_id="O4" value="-0.53" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.569</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar size percent was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.770</ci_lower_limit>
            <ci_upper_limit>1.687</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.767</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar size percent was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.792</ci_lower_limit>
            <ci_upper_limit>1.457</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.261</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar size percent was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.965</ci_lower_limit>
            <ci_upper_limit>0.921</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar size percent was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.261</ci_lower_limit>
            <ci_upper_limit>2.222</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.994</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar size percent was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.763</ci_lower_limit>
            <ci_upper_limit>2.014</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.639</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar size percent was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.993</ci_lower_limit>
            <ci_upper_limit>1.283</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Scar Tissue Mass (DEMRI)</title>
        <description>Change in scar tissue mass as assessed via cardiac MRI</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available and analyzable scar size data at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scar Tissue Mass (DEMRI)</title>
          <description>Change in scar tissue mass as assessed via cardiac MRI</description>
          <population>Participants with available and analyzable scar size data at baseline and 6 months</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="5.21"/>
                    <measurement group_id="O2" value="-1.13" spread="3.71"/>
                    <measurement group_id="O3" value="-2.51" spread="4.51"/>
                    <measurement group_id="O4" value="-1.31" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.992</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar tissue mass was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.437</ci_lower_limit>
            <ci_upper_limit>3.319</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.862</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar tissue mass was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.278</ci_lower_limit>
            <ci_upper_limit>2.643</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.217</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar tissue mass was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.846</ci_lower_limit>
            <ci_upper_limit>1.443</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.327</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar tissue mass was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.325</ci_lower_limit>
            <ci_upper_limit>4.611</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.859</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar tissue mass was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.551</ci_lower_limit>
            <ci_upper_limit>3.068</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.338</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in scar tissue mass was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.952</ci_lower_limit>
            <ci_upper_limit>1.184</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t-test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maximal Oxygen Consumption (Peak VO2)</title>
        <description>Change in maximal oxygen consumption (peak V02) as assessed via treadmill</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable peak VO2 data from baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximal Oxygen Consumption (Peak VO2)</title>
          <description>Change in maximal oxygen consumption (peak V02) as assessed via treadmill</description>
          <population>Participants with available analyzable peak VO2 data from baseline and 6 months</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="2.94"/>
                    <measurement group_id="O2" value="-0.83" spread="3.75"/>
                    <measurement group_id="O3" value="0.77" spread="2.86"/>
                    <measurement group_id="O4" value="0.13" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in peak VO2 was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.456</ci_lower_limit>
            <ci_upper_limit>0.411</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.428</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in peak VO2 was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.798</ci_lower_limit>
            <ci_upper_limit>0.859</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.382</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in peak VO2 was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>2.093</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in peak VO2 was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.255</ci_lower_limit>
            <ci_upper_limit>-0.052</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.610</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in peak VO2 was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.991</ci_lower_limit>
            <ci_upper_limit>1.885</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in peak VO2 was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.356</ci_lower_limit>
            <ci_upper_limit>3.557</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Exercise Tolerance (Six Minute Walk Test)</title>
        <description>Change in distance walked (in meters) as measured by the 6 minute walk test. Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable exercise tolerance data at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Exercise Tolerance (Six Minute Walk Test)</title>
          <description>Change in distance walked (in meters) as measured by the 6 minute walk test. Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis.</description>
          <population>Participants with available analyzable exercise tolerance data at baseline and 6 months</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.24" spread="71.65"/>
                    <measurement group_id="O2" value="23.85" spread="57.03"/>
                    <measurement group_id="O3" value="2.36" spread="44.30"/>
                    <measurement group_id="O4" value="0.67" spread="70.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in exercise tolerance was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.537</ci_lower_limit>
            <ci_upper_limit>56.687</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.230</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in exercise tolerance was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.759</ci_lower_limit>
            <ci_upper_limit>59.134</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.905</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in exercise tolerance was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.974</ci_lower_limit>
            <ci_upper_limit>34.361</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.335</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in exercise tolerance was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.267</ci_lower_limit>
            <ci_upper_limit>49.030</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.827</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in exercise tolerance was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.106</ci_lower_limit>
            <ci_upper_limit>30.880</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in exercise tolerance was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-21.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.989</ci_lower_limit>
            <ci_upper_limit>8.001</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score</title>
        <description>Change in the quality of life summary score as measured by the Minnesota Living with Heart Failure Questionnaire. Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable MLHFQ summary score at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score</title>
          <description>Change in the quality of life summary score as measured by the Minnesota Living with Heart Failure Questionnaire. Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes.</description>
          <population>Participants with available analyzable MLHFQ summary score at baseline and 6 months</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.32" spread="16.94"/>
                    <measurement group_id="O2" value="-20.78" spread="23.11"/>
                    <measurement group_id="O3" value="-8.65" spread="23.72"/>
                    <measurement group_id="O4" value="-5.68" spread="18.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in MLHFQ summary score was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.915</ci_lower_limit>
            <ci_upper_limit>-0.357</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in MLHFQ summary score was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.871</ci_lower_limit>
            <ci_upper_limit>-3.319</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.119</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in MLHFQ summary score was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.784</ci_lower_limit>
            <ci_upper_limit>8.836</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.845</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in MLHFQ summary score was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.087</ci_lower_limit>
            <ci_upper_limit>4.762</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.976</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in MLHFQ summary score was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.931</ci_lower_limit>
            <ci_upper_limit>16.848</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.717</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in MLHFQ summary score was compared using ANCOVA analyses adjusting for baseline values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.337</ci_lower_limit>
            <ci_upper_limit>25.578</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)</title>
        <description>Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via laboratory blood draw</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with available analyzable NT-proBNP values at baseline and 6 months. Log transformation used. P-values obtained from transformed data.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)</title>
          <description>Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via laboratory blood draw</description>
          <population>Participants with available analyzable NT-proBNP values at baseline and 6 months. Log transformation used. P-values obtained from transformed data.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-724.46" spread="4020.53"/>
                    <measurement group_id="O2" value="52.6" spread="586.16"/>
                    <measurement group_id="O3" value="204.09" spread="533.51"/>
                    <measurement group_id="O4" value="687.25" spread="2006.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.110</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in NT-proBNP value compared using ANCOVA analyses adjusting for baseline values. Data log transformed, p-values obtained from transformed data</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1411.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>840.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3108.3</ci_lower_limit>
            <ci_upper_limit>284.9</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.112</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in NT-proBNP value compared using ANCOVA analyses adjusting for baseline values. Data log transformed, p-values obtained from transformed data</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-634.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>405.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1460.7</ci_lower_limit>
            <ci_upper_limit>191.4</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.891</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in NT-proBNP value compared using ANCOVA analyses adjusting for baseline values. Data log transformed, p-values obtained from transformed data</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-483.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>400.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1301.5</ci_lower_limit>
            <ci_upper_limit>335.2</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in NT-proBNP value compared using ANCOVA analyses adjusting for baseline values. Data log transformed, p-values obtained from transformed data</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-928.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>754.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2470.7</ci_lower_limit>
            <ci_upper_limit>613.6</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.661</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in NT-proBNP value compared using ANCOVA analyses adjusting for baseline values. Data log transformed, p-values obtained from transformed data</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-777.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>756.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2323.2</ci_lower_limit>
            <ci_upper_limit>769.1</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in NT-proBNP value compared using ANCOVA analyses adjusting for baseline values. Data log transformed, p-values obtained from transformed data</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>151.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>162.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-175.4</ci_lower_limit>
            <ci_upper_limit>478.4</ci_upper_limit>
            <estimate_desc>Confidence intervals based on t test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable LVEF at baseline, 6 months, and 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable LVEF at baseline, 6 months, and 12 months.</population>
          <units>percentage of end diastolic volume</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" spread="0.551"/>
                    <measurement group_id="O2" value="0.422" spread="0.480"/>
                    <measurement group_id="O3" value="0.633" spread="0.411"/>
                    <measurement group_id="O4" value="-0.175" spread="0.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.269</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>0.267</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.241</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Global Strain (HARP MRI)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had available analyzable global circumferential strain at baseline, 6 month, and 12 month.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Strain (HARP MRI)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had available analyzable global circumferential strain at baseline, 6 month, and 12 month.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.126" spread="0.239"/>
                    <measurement group_id="O2" value="-0.324" spread="0.283"/>
                    <measurement group_id="O3" value="0.276" spread="0.300"/>
                    <measurement group_id="O4" value="0.576" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.153</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Regional Strain (HARP MRI)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable regional strain at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Regional Strain (HARP MRI)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable regional strain at baseline, 6 months, and 12 months</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.084" spread="0.287"/>
                    <measurement group_id="O2" value="-0.385" spread="0.350"/>
                    <measurement group_id="O3" value="-0.325" spread="0.323"/>
                    <measurement group_id="O4" value="-0.288" spread="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>-0.267</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.164</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable LVEDVI at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable LVEDVI at baseline, 6 months, and 12 months</population>
          <units>mL/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="1.585"/>
                    <measurement group_id="O2" value="0.320" spread="1.303"/>
                    <measurement group_id="O3" value="1.796" spread="1.393"/>
                    <measurement group_id="O4" value="1.862" spread="1.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>1.395</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.829</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, 12 months)</time_frame>
        <population>Participants who had analyzable LVESVI at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable LVESVI at baseline, 6 months, and 12 months</population>
          <units>mL/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.826" spread="1.158"/>
                    <measurement group_id="O2" value="-0.394" spread="1.117"/>
                    <measurement group_id="O3" value="0.626" spread="1.288"/>
                    <measurement group_id="O4" value="1.077" spread="1.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.379</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>0.603</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.683</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular Sphericity Index-Trajectory</title>
        <description>Sphericity index is the ratio of the long and short axis measurements of the left ventricle. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable LV Sphericity Index at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular Sphericity Index-Trajectory</title>
          <description>Sphericity index is the ratio of the long and short axis measurements of the left ventricle. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable LV Sphericity Index at baseline, 6 months, and 12 months</population>
          <units>ratio-unitless</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.007"/>
                    <measurement group_id="O2" value="-0.004" spread="0.008"/>
                    <measurement group_id="O3" value="0.008" spread="0.007"/>
                    <measurement group_id="O4" value="0.002" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.004</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Scar Size Percent (DEMRI)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable scar size percent at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scar Size Percent (DEMRI)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable scar size percent at baseline, 6 months, and 12 months</population>
          <units>percentage of mass</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.341" spread="0.314"/>
                    <measurement group_id="O2" value="-0.290" spread="0.231"/>
                    <measurement group_id="O3" value="-0.427" spread="0.306"/>
                    <measurement group_id="O4" value="-0.013" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.126</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>-0.244</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.158</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable scar size data at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable scar size data at baseline, 6 months, and 12 months</population>
          <units>grams</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.309" spread="0.539"/>
                    <measurement group_id="O2" value="-0.266" spread="0.367"/>
                    <measurement group_id="O3" value="-0.958" spread="0.615"/>
                    <measurement group_id="O4" value="-0.390" spread="0.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>-0.420</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.281</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory</title>
        <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable peak VO2 at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory</title>
          <description>The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable peak VO2 at baseline, 6 months, and 12 months</population>
          <units>ml/kg/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.711" spread="0.352"/>
                    <measurement group_id="O2" value="0.632" spread="0.275"/>
                    <measurement group_id="O3" value="-0.165" spread="0.325"/>
                    <measurement group_id="O4" value="-0.093" spread="0.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.472</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>-0.133</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.184</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory</title>
        <description>Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable six minute walk tests at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory</title>
          <description>Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable six minute walk tests at baseline, 6 months, and 12 months</population>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.996" spread="5.558"/>
                    <measurement group_id="O2" value="11.434" spread="5.531"/>
                    <measurement group_id="O3" value="6.776" spread="6.192"/>
                    <measurement group_id="O4" value="-4.248" spread="5.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>6.544</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.882</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory</title>
        <description>Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The 2nd and 3rd set of results represent differences for varying slopes from the interaction model.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable MLHFQ scores at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory</title>
          <description>Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The 2nd and 3rd set of results represent differences for varying slopes from the interaction model.</description>
          <population>Participants who had analyzable MLHFQ scores at baseline, 6 months, and 12 months</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.258" spread="2.079"/>
                    <measurement group_id="O2" value="-7.295" spread="2.746"/>
                    <measurement group_id="O3" value="0.776" spread="1.731"/>
                    <measurement group_id="O4" value="-2.378" spread="2.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. A time by treatment interaction was assessed.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Regression, Linear</method>
            <param_type>slope with interaction</param_type>
            <param_value>-7.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.3</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. A time by treatment interaction was assessed.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Regression, Linear</method>
            <param_type>slope with interaction</param_type>
            <param_value>-6.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory</title>
        <description>Log transformation used. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
        <time_frame>Assessed as a trajectory (baseline, 6 months, and 12 months)</time_frame>
        <population>Participants who had analyzable NT-proBNP values at baseline, 6 months, and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory</title>
          <description>Log transformation used. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm.</description>
          <population>Participants who had analyzable NT-proBNP values at baseline, 6 months, and 12 months</population>
          <units>pg/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.650" spread="72.303"/>
                    <measurement group_id="O2" value="102.250" spread="46.194"/>
                    <measurement group_id="O3" value="61.680" spread="57.365"/>
                    <measurement group_id="O4" value="185.210" spread="99.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures linear regression models were used to address trajectories (upward or downward trends) over time within each of the 4 treatment groups. Results of the overall model are reported.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <p_value_desc>No adjustments for multiplicity were made in this Phase II trial</p_value_desc>
            <method>Repeated Measures Linear Regression</method>
            <param_type>slope of time</param_type>
            <param_value>84.557</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>35.810</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>&quot;Standard error of the mean&quot; is the standard error of the estimate of the slope of time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Major Adverse Cardiac Events (MACE)</title>
        <description>Number of participants with adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization).</description>
        <time_frame>Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection</time_frame>
        <population>Population includes all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Major Adverse Cardiac Events (MACE)</title>
          <description>Number of participants with adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization).</description>
          <population>Population includes all randomized participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants Experiencing Other Significant Clinical Events</title>
        <description>Number of participants experiencing other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade</description>
        <time_frame>Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection</time_frame>
        <population>Population includes all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Experiencing Other Significant Clinical Events</title>
          <description>Number of participants experiencing other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade</description>
          <population>Population includes all randomized participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Days Alive and Out of Hospital for Heart Failure</title>
        <description>Days alive and out of hospital during the study evaluation period. Subjects were allotted a visit window extending 30 days past their anticipated 12-month visit. Some participants had extended 12-month visit windows due to the COVID-19 pandemic.</description>
        <time_frame>Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection</time_frame>
        <population>Comparison of the 4 treatment groups on days alive and out of the hospital for heart failure during the 12 month study evaluation period; adjusted for time in followup. Analysis includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Days Alive and Out of Hospital for Heart Failure</title>
          <description>Days alive and out of hospital during the study evaluation period. Subjects were allotted a visit window extending 30 days past their anticipated 12-month visit. Some participants had extended 12-month visit windows due to the COVID-19 pandemic.</description>
          <population>Comparison of the 4 treatment groups on days alive and out of the hospital for heart failure during the 12 month study evaluation period; adjusted for time in followup. Analysis includes all randomized participants.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472" spread="121"/>
                    <measurement group_id="O2" value="448" spread="120"/>
                    <measurement group_id="O3" value="438" spread="163"/>
                    <measurement group_id="O4" value="427" spread="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects With Events Between Randomization and Study Product Injection (SPI) That Preclude the Receipt of Product</title>
        <description>Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product. Reasons include those who did not undergo harvest (n=6; death, subject withdraw, subject changed mind) and those who did not undergo SPI (n=9; death, LVAD placement, episodes of ventricular tachycardia, and cancelled procedures)</description>
        <time_frame>Randomization to SPI, an average of 14 weeks</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Events Between Randomization and Study Product Injection (SPI) That Preclude the Receipt of Product</title>
          <description>Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product. Reasons include those who did not undergo harvest (n=6; death, subject withdraw, subject changed mind) and those who did not undergo SPI (n=9; death, LVAD placement, episodes of ventricular tachycardia, and cancelled procedures)</description>
          <population>All randomized participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects Who Have a Failed Bone Marrow Aspiration Procedure</title>
        <description>Number and percent of subjects who do not successfully undergo bone marrow aspiration</description>
        <time_frame>During bone marrow aspiration procedure</time_frame>
        <population>Participants who attended their harvest visit</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Have a Failed Bone Marrow Aspiration Procedure</title>
          <description>Number and percent of subjects who do not successfully undergo bone marrow aspiration</description>
          <population>Participants who attended their harvest visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects Who Have a Failed Endomyocardial Biopsy Procedure</title>
        <description>Number and percent of subjects who do not successfully undergo endomyocardial biopsy procedure. Note only participants who were assigned to MSC+CPC or to CPC groups had endomyocardial biopsy procedures attempted.</description>
        <time_frame>During endomyocardial biopsy procedure</time_frame>
        <population>Participants who attended the harvest visit and were assigned to either MSCs+CPCs or CPCs.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Have a Failed Endomyocardial Biopsy Procedure</title>
          <description>Number and percent of subjects who do not successfully undergo endomyocardial biopsy procedure. Note only participants who were assigned to MSC+CPC or to CPC groups had endomyocardial biopsy procedures attempted.</description>
          <population>Participants who attended the harvest visit and were assigned to either MSCs+CPCs or CPCs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject MSC Products Which Failed Release Criteria</title>
        <description>Number and percent of subjects who have MSC products which failed release criteria</description>
        <time_frame>Harvest to Study Product Injection Procedure</time_frame>
        <population>Population includes only those participant products assigned to treatment groups including MSCs.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Subject MSC Products Which Failed Release Criteria</title>
          <description>Number and percent of subjects who have MSC products which failed release criteria</description>
          <population>Population includes only those participant products assigned to treatment groups including MSCs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject CPC Products Which Failed Release Criteria</title>
        <description>Number and percent of subjects who have CPC products which failed release criteria</description>
        <time_frame>Harvest to Study Project Injection procedure</time_frame>
        <population>Population includes only those participant products assigned to treatment groups including CPCs.</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Subject CPC Products Which Failed Release Criteria</title>
          <description>Number and percent of subjects who have CPC products which failed release criteria</description>
          <population>Population includes only those participant products assigned to treatment groups including CPCs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects Who Receive Less Than 15 Injections During SPI</title>
        <description>Number and percent of subjects who received less than 15 injections during SPI</description>
        <time_frame>During SPI procedure</time_frame>
        <population>Participants who received study product administration</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Receive Less Than 15 Injections During SPI</title>
          <description>Number and percent of subjects who received less than 15 injections during SPI</description>
          <population>Participants who received study product administration</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable</title>
        <description>Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Participants completing an MRI scan at both baseline and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MSCs + CPCs</title>
            <description>Target dose of 150 million MSCs and 5 million CPCs</description>
          </group>
          <group group_id="O2">
            <title>MSCs</title>
            <description>Target dose of 150 million MSCs</description>
          </group>
          <group group_id="O3">
            <title>CPCs</title>
            <description>Target dose of 5 million CPCs</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Plasmalyte A</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable</title>
          <description>Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure</description>
          <population>Participants completing an MRI scan at both baseline and 12 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events reported occurred between randomization and the end of 12 Month Visit Window (an average of 395 days following study product injection).</time_frame>
      <desc>Events were assessed systematically at each study visit during the physical exam assessment. A standard workbook was used to collect event details. Sponsor safety team reviewed events and requested additional documentation as needed.</desc>
      <group_list>
        <group group_id="E1">
          <title>MSCs + CPCs</title>
          <description>Target dose of 150 million MSCs and 5 million CPCs</description>
        </group>
        <group group_id="E2">
          <title>MSCs</title>
          <description>Target dose of 150 million MSCs</description>
        </group>
        <group group_id="E3">
          <title>CPCs</title>
          <description>Target dose of 5 million CPCs</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Plasmalyte A</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia or Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Angina pectoris or angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="20" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Medical device site erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vascular access site pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Device inappropriate shock delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ventricular assist device insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris or angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively small group sizes overall. Relatively long interval between harvest visit and study product injection (approx. 14wks) resulting in patient attrition. Failure of cells to grow from tissue of some patients, resulting in some patients crossing over into other treatment groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shelly Sayre, M.P.H. Project Manager</name_or_title>
      <organization>University of Texas-Houston School of Public Health</organization>
      <phone>713-500-9529</phone>
      <email>Shelly.L.Sayre@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

